This team is led by Distinguished Professor Fang Hsu-Wei, Director of the Well-being and Health Industry Accelerator Center, a university-level R&D center of National Taipei University of Technology. Utilizing the patents for new suture materials and barbed manufacturing processes from Professor Fang's team, along with the capability of rapid commercialization processes, the team aims to resolve the six major pain points of current barbed medical sutures in Taiwan:
1. Developing new suture materials to produce long-lasting barbed medical sutures that stimulate collagen production.
2. Utilizing composite processing of cutting and molding to improve the mechanical properties of the barbs, enhancing grip strength and reducing discomfort caused by surface protrusions.
3. Designing diversified specifications to meet different lifting functional requirements.
4. Localizing the production of medical devices to remain unaffected by international situations.
5. Providing legal barbed medical sutures with lifting as the indicated use.

微科生醫股份有限公司 possesses an exceptionally strong independent R&D and rapid commercialization team for biomedical materials. Its core technologies include the development of long-lasting new suture materials, medical device surface processing and modification technologies, composite barb patents, and experience in the rapid integration of medical device commercialization. The company develops a brand-new generation of "innovative long-lasting barbed sutures" to effectively solve clinical pain points. Furthermore, by utilizing the unique in vitro barb testing platform established by the team, combined with the development of surgical techniques by clinicians, it constructs a comprehensive lifting strategy evaluation platform to provide all-around, effective solutions, thereby enhancing the output value and international competitiveness of Taiwan's high-end medical devices.